Ropes & Gray’s M&A Deal Teams Achieve Outstanding Quarter
Ropes & Gray’s M&A attorneys achieved a top six ranking in The Deal’s M&A Power Rankings in the second quarter fueled by its work on a series of large and significant transactions. The firm’s stellar transactional accomplishments were further punctuated by the work of its private equity team which secured a top three ranking from The Deal.
Our M&A attorneys counseled Gilead Sciences Inc. in its exclusive option to acquire Tizona Therapeutics in a deal valued up to $1.5 billion as well as its exclusive option to acquire Pionyr Immunotherapeutics in a transactions valued as high as $1.74 billion. A team guided Novavax in its acquisition of Praha Vaccines, a deal that will be instrumental to the company’s anticipated production of a COVID-19 vaccine. Additionally, Ropes & Gray’s represented Advent International in its initial and renegotiated agreement to acquire Forescout Technologies.
The firm’s approximately 200 M&A and private equity attorneys advised on more than 280 transactions over the past 18 months for an aggregate total of more than $170 billion demonstrating the skills and attention to client needs that are the hallmark of Ropes & Gray.